基于卡介苗感染过程中MAPK-Mcl-1信号通路和巨噬细胞极化调控机制的生物信息学分析及其实验验证

doi:10.13481/j.1671-587X.20260216

Abstract

Abstract:

Objective To discuss the role of mitogen-activated protein kinase （MAPK）-myeloid cell leukemia sequence 1 （Mcl-1） signaling axis in the polarization process of macrophages infected with Bacillus Calmette-Guérin （BCG）， and to clarify its possible molecular mechanism. Methods The transcriptome sequencing data of GSE89391 and GSE51029 were downloaded from Gene Expression Omnibus （GEO） database， and the MAPK signaling pathway-related gene sets were downloaded from Molecular Signatures Database （MSigDB）. The gene set variation analysis （GSVA） package was used to perform single-sample gene set enrichment analysis （ssGSEA） on the macrophage data in GEO database， and the activity scores of MAPK signaling pathway were calculated. The infected samples were divided into Mcl-1 high expression group and Mcl-1 low expression group according to the median of Mcl-1 expression level， and gene set enrichment analysis （GSEA） was performed. Spearman correlation analysis was used to assess the correlation between Mcl-1 expression level and MAPK pathway activity in macrophages in GEO database. The extracellular signal-regulated kinase （ERK） pathway blocker PD98059 （50 μmol·L?1）， c-Jun N-terminal kinase （JNK） pathway blocker SP600125 （30 μmol·L?1）， and p38 pathway blocker SB203580 （60 μmol·L?1） were prepared.The Raw264.7 cells were divided into control group， various blocker-treated groups， BCG group， and various blocker-treated groups after BCG infection. BCG bacterial solution was prepared and used to infect the cells in corresponding groups， and the corresponding blockers were added to the cells in various groups. The cell supernatants and cell samples in various groups were collected at 0， 12， and 24 h after treatment. Enzyme-linked immunosorbent assay （ELISA） method was used to detect the levels of Mcl-1， interleukin-6 （IL-6）， tumor necrosis factor-α （TNF-α）， interleukin-10 （IL-10）， and transforming growth factor-β （TGF-β） in supernatant of the macrophages in various groups； real-time fluorescence quantitative PCR （RT-qPCR） method was used to detect the expression levels of M1 marker inducible nitric oxide synthase （iNOS） mRNA and M2 marker found in inflammatory zone 1 （Fizz1） mRNA in the macrophages in various groups. Results Based on GEO databases， compared with uninfected control macrophages， the level of Mcl-1 gene in the macrophages infected with Mycobacterium tuberculosis（MTB） was significantly increased （P<0.05）. The ssGSEA analysis results showed that compared with uninfected control macrophages， the MAPK signaling pathway activity score in MTB-infected macrophages was significantly increased （P<0.05）. The GSEA analysis results revealed that differentially expressed genes in Mcl-1 high expression groups were significantly enriched in the MAPK pathway （P<0.05）. The Spearman correlation analysis results indicated there was a positive correlation between the expression level of Mcl-1 gene and MAPK signaling pathway activity score （P<0.05）. At 12 and 24 h after treatment， compared with BCG group， the levels of Mcl-1 in supernatant of the macrophages in various blocker-treated groups were significantly decreased （P<0.05）. At 12 h after treatment， compared with control group， the levels of IL-6 and TNF-α in supernatant of the macrophages in BCG group were significantly increased （P<0.05）. Compared with BCG group， the levels of IL-6 and TNF-α in supernatants of the macrophages in BCG+SP and BCG+PD+SP groups were significantly decreased （P<0.05）. At 24 h after treatment， compared with control group， the level of TNF-α in supernatant of the macrophages in BCG group was significantly increased （P<0.05）. Compared with BCG group， the levels of IL-6 in supernatants of the macrophages in BCG+PD， BCG+SP， BCG+SB， and BCG+PD+SP groups were significantly decreased （P<0.05）， and the levels of TNF-α in supernatants of the macrophages in all blocker-treated groups were significantly decreased （P<0.05）. At 12 h after treatment， compared with control group， the level of TGF-β in supernatant of the macrophages in BCG group was significantly increased （P<0.05）. Compared with BCG group， the levels of TGF-β in supernatants of the macrophages in BCG+SP， BCG+PD+SP， BCG+PD+SB， BCG+SP+SB， and BCG+PD+SP+SB groups were significantly increased （P<0.05）. At 24 h after treatment， compared with control group， the level of IL-10 in supernatant of the macrophages in BCG group was significantly increased （P<0.05）. Compared with BCG group， the levels of IL-10 and TGF-β in supernatants of the macrophages in BCG+PD， BCG+SP， BCG+PD+SP， BCG+PD+SB， and BCG+SP+SB groups were significantly decreased （P<0.05）. At 0 h after infection， compared with control group， the expression levels of iNOS and Fizz1 mRNA in the macrophages in BCG group were significantly increased （P<0.05）. At 12 h after treatment， compared with control group， the expression level of iNOS mRNA in the macrophages in BCG group was significantly decreased （P<0.01）， while the expression level of Fizz1 mRNA was significantly increased （P<0.01）. Compared with BCG group， the expression levels of iNOS mRNA in the macrophages in all blocker-treated groups were significantly increased （P<0.01）， and the expression levels of Fizz1 mRNA in the macrophages in BCG+PD， BCG+PD+SP， BCG+PD+SB， BCG+SP+SB， and BCG+PD+SP+SB groups were significantly increased （P<0.01）. At 24 h after treatment， compared with control group， the expression levels of iNOS and Fizz1 mRNA in the macrophages in BCG group were significantly increased （P<0.05）. The expression levels of iNOS mRNA in the macrophages between BCG group and all blocker-treated groups showed no statistically significant difference （P>0.05）. Compared with BCG group， the expression level of Fizz1 mRNA in the macrophages in BCG+PD+SP group was significantly decreased （P<0.01）. Conclusion MAPK signaling pathway may mediate the polarization process of macrophages infected with BCG by regulating Mcl-1 activity， in which the JNK pathway plays a core regulatory role， and the p38 and ERK pathways are synergistically involved in the regulation.

Key words: Bioinformatics, Bacillus Calmette-Guérin, Macrophage polarization, Myeloid cell leukemia sequence 1, Mitogen-activated protein kinase signaling pathway, c-Jun N-terminal kinase

CLC Number:

R363.2

Ruihan GE,Chen LI,Shengpeng WANG,Yang LU,Caixia TAN,Haotian CUI,Xinmin WANG,Le ZHANG. Bioinformatic analysis on regulatory mechanism of MAPK-Mcl-1 signaling pathway and macrophage polarization during Bacillus Calmette-Guérin infection and its experimental validation[J].Journal of Jilin University(Medicine Edition), 2026, 52(2): 440-450.

Figures/Tables 9

Tab.1

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Tab.2

Tab.3

Tab.4

Tab.5

References 23

[1]	LANGE C， AABY P， BEHR M A， et al. 100 years of Mycobacterium bovis Bacille Calmette-Guérin［J］. Lancet Infect Dis， 2022， 22（1）： e2-e12.
[2]	CHEN J J， GAO L， WU X Y， et al. BCG-induced trained immunity： history， mechanisms and potential applications［J］. J Transl Med， 2023， 21（1）： 106.
[3]	BICKETT T E， MCLEAN J， CREISSEN E， et al. Characterizing the BCG induced macrophage and neutrophil mechanisms for defense against Mycobacterium tuberculosis ［J］. Front Immunol， 2020， 11： 1202.
[4]	LIU L M， SHI W J， XIAO X， et al. BCG immunotherapy inhibits cancer progression by promoting the M1 macrophage differentiation of THP-1 cells via the Rb/E2F1 pathway in cervical carcinoma［J］. Oncol Rep， 2021， 46（5）： 245.
[5]	CHOI Y Y， HAN M S， LEE H J， et al. Mycobacterium bovis osteitis following immunization with Bacille Calmette-Guérin （BCG） in Korea［J］. J Korean Med Sci， 2018， 34（1）： e3.
[6]	殷立晗，李昕，徐正中，等. 结核分枝杆菌亚单位疫苗研究进展［J］. 中国人兽共患病学报， 2023， 39（5）： 492-499.
[7]	KURSCHAT C， METZ A， KIRSCHNEK S， et al. Importance of Bcl-2-family proteins in murine hematopoietic progenitor and early B cells［J］. Cell Death Dis， 2021， 12（8）： 784.
[8]	TANTAWY S I， TIMOFEEVA N， SARKAR A， et al. Targeting MCL-1 protein to treat cancer： opportunities and challenges［J］. Front Oncol， 2023， 13： 1226289.
[9]	冒婷，徐铭益，王佳轶. 非酒精性脂肪性肝炎小鼠模型肝组织T淋巴细胞的特征分析［J］. 临床肝胆病杂志， 2025， 41（3）： 461-468.
[10]	OPYDO M， MLYCZYŃSKA A， MLYCZYŃSKA E， et al. Synergistic action of MCL-1 inhibitor with BCL-2/BCL-XL or MAPK pathway inhibitors enhances acute myeloid leukemia cell apoptosis and differentiation［J］. Int J Mol Sci， 2023， 24（8）： 7180.
[11]	HAN L， LU Y， WANG X F， et al. Regulatory role and mechanism of the inhibition of the Mcl-1 pathway during apoptosis and polarization of H37Rv-infected macrophages［J］. Medicine， 2020， 99（42）： e22438.
[12]	LI J L， LU J B， WANG G Z， et al. Past， present and future of Bacille Calmette-Guérin vaccine use in China［J］. Vaccines， 2022， 10（7）： 1157.
[13]	郑伟. H37Rv与BCG感染BoMac源外泌体对巨噬细胞极化作用的研究［D］. 长春：吉林农业大学， 2023.
[14]	CHO H， KWON H Y， SHARMA A， et al. Visualizing inflammation with an M1 macrophage selective probe via GLUT1 as the gating target［J］. Nat Commun， 2022， 13（1）： 5974.
[15]	周筱雨，胡良皞，李兆申. 慢性胰腺炎干细胞治疗研究进展［J］. 中国实用内科杂志， 2024， 44（7）： 547-552.
[16]	邢国静，王丽菲，罗龙龙，等. 巨噬细胞极化在药物性肝损伤中的作用研究进展［J］. 解放军医学杂志， 2025， 50（11）： 1478-1484.
[17]	LUO M， ZHAO F K， CHENG H， et al. Macrophage polarization： an important role in inflammatory diseases［J］. Front Immunol， 2024， 15： 1352946.
[18]	MOLINA-OLVERA G， RIVAS-ORTIZ C I， SCHCOLNIK-CABRERA A， et al. RNA microarray-based comparison of innate immune phenotypes between human THP-1 macrophages stimulated with two BCG strains［J］. Int J Mol Sci， 2022， 23（9）： 4525.
[19]	唐怡，王国泰，蒋雨涵，等. 中药调控肿瘤相关巨噬细胞对肝细胞癌的治疗作用与机制［J］. 临床肝胆病杂志， 2025， 41（6）： 1199-1206.
[20]	BO H T， MOURE U A E， YANG Y M， et al. Mycobacterium tuberculosis-macrophage interaction： Molecular updates［J］. Front Cell Infect Microbiol， 2023， 13： 1062963.
[21]	王飞雨，王新敏，王婵，等. 靶向沉默Mcl-1基因对感染不同毒力结核杆菌小鼠腹腔巨噬细胞凋亡的影响［J］. 中国病理生理杂志， 2015， 31（12）： 2195-2201.
[22]	卢洋，王新敏，王小芳，等. 下调Bcl-2家族蛋白促进MTB感染的小鼠巨噬细胞系凋亡［J］. 基础医学与临床， 2018， 38（10）： 1383-1388.
[23]	LI P， LI Y， WANG C C， et al. Comparative transcriptomics reveals common and strain-specific responses of human macrophages to infection with Mycobacterium tuberculosis and Mycobacterium bovis BCG［J］. Microb Pathog， 2024， 189： 106593.

Gene	Sequence (5'-3')	Length (bp)
iNOS	F:TGATGTGCTGCCTCTGGTCT	20
	R:GAGCTCCTGGAACCACTCGT	20
Fizzl	F:GAGATCCAGAGTGGAGATACTTGC	24
	R:TCTTAGGACAGTTGGCAGCAG	21
β-actin	F:GTGACGTTGACATCCGTAAAGA	22
	R:GCCGGACTCATCGTACTCC	19

Group	Mcl-1 level
Group	(t/h) 0	12	24
Control	0.48±0.02	1.04±0.03	1.51±0.14
BCG	0.46±0.06	0.76±0.01^*	1.06±0.04^*
BCG+PD	-	0.57±0.04^△	0.57±0.02^△
BCG+SP	-	0.42±0.05^△	0.47±0.06^△
BCG+SB	-	0.36±0.12^△	0.52±0.08^△
BCG+PD+SP	-	0.41±0.06^△	0.57±0.02^△
BCG+PD+SB	-	0.39±0.03^△	0.47±0.01^△
BCG+SP+SB	-	0.34±0.07^△	0.43±0.02^△
BCG+PD+SP+SB	-	0.39±0.08^△	0.45±0.02^△

Group	IL-6			TNF-α
Group	(t/h) 0	12	24	0	12	24
Control	84.14±20.02	166.27±7.46	51.77±1.22	68.08±2.52	161.55±13.85	158.81±4.73
BCG	81.64±7.21	290.38±9.21^*	59.89±3.17	74.82±1.88	194.20±5.66^*	177.32±2.87^*
BCG+PD	-	190.40±15.20	44.75±2.94^△	-	160.45±41.96^△	97.91±1.93^△
BCG+SP	-	145.61±13.49^△	42.28±2.45^△	-	161.56±20.18^△	81.86±2.72^△
BCG+SB	-	205.32±10.09	47.47±2.44^△	-	165.15±5.54^△	86.03±2.07^△
BCG+PD+SP	-	183.54±16.04^△	43.15±1.22^△	-	165.91±19.06^△	64.18±3.37^△
BCG+PD+SB	-	170.24±18.08	56.92±1.21	-	163.68±18.87^△	50.81±2.95^△
BCG+SP+SB	-	254.15±16.04	53.49±3.64	-	195.58±12.93	58.43±7.20^△
BCG+PD+SP+SB	-	224.85±17.00	82.50±1.20^△	-	200.75±7.20	69.23±2.32^△

Group	IL-10			TGF-β
Group	（t/h） 0	12	24	0	12	24
Control	34.69±11.47	27.89±3.42	53.58±5.07	72.74±4.73	314.72±9.84	424.23±7.36
BCG	43.57±10.66	31.47±5.47	71.77±2.68^*	79.52±5.69	379.25±17.08^*	464.49±3.65
BCG+PD	-	38.65±1.85	52.26±5.95^△	-	396.45±18.38	289.72±7.69^△
BCG+SP	-	32.45±5.77	56.22±2.03^△	-	424.21±16.88^△	368.48±9.90^△
BCG+SB	-	35.38±2.26	66.16±7.03	-	394.31±9.83	477.11±18.24
BCG+PD+SP	-	33.42±1.07	63.54±4.16^△	-	411.40±23.13^△	320.59±11.41^△
BCG+PD+SB	-	38.66±6.24	65.09±2.80^△	-	426.28±31.43^△	348.98±7.53^△
BCG+SP+SB	-	37.01±3.60	64.42±3.24^△	-	436.96±16.86^△	348.98±3.76^△
BCG+PD+SP+SB	-	37.34±1.07	56.35±1.65^△	-	493.91±16.65^△	469.92±14.51

Group	iNOS			Fizz1
Group	（t/h） 0	12	24	0	12	24
Control	1.00±0.10	1.00±0.10	1.00±0.10	1.00±0.10	1.00±0.10	1.00±0.10
PD	-	1.33±0.13	0.54±0.05^*	-	1.24±0.66	0.31±0.04^*
SP	-	1.60±0.13	0.84±0.11^*	-	1.49±0.64	0.26±0.10^*
SB	-	2.31±0.17^**	0.48±0.08^*	-	4.43±2.13^*	0.41±0.11^*
PD+SP	-	2.02±0.88^**	1.00±0.14	-	8.27±0.64^*	0.77±0.12^*
PD+SB	-	2.15±0.04^**	0.74±0.09^*	-	2.69±0.89^*	0.22±0.01^*
SP+SB	-	1.35±0.09	0.61±0.04^*	-	6.59±0.27^*	0.18±0.08^*
PD+SP+SB	-	0.76±0.23	0.61±0.06	-	2.44±0.90^*	0.83±0.20^*
BCG	1.34±0.07^*	0.50±0.03^**	1.86±0.10^*	1.43±0.21^*	2.42±0.48^**	32.32±1.12^*
BCG+PD	-	1.57±0.14^△△	0.64±0.09	-	3.48±0.36^△	24.24±3.66
BCG+SP	-	1.59±0.15^△△	0.87±0.03	-	1.45±0.63	29.51±0.41
BCG+SB	-	1.94±0.13^△△	0.52±0.06	-	1.49±0.40	24.65±2.17
BCG+PD+SP	-	2.19±0.06^△△	1.19±0.18	-	15.98±0.91^△△	2.87±0.32^△△
BCG+PD+SB	-	2.56±0.12^△△	0.91±0.02	-	8.16±0.76^△△	32.88±1.76
BCG+SP+SB	-	1.35±0.22^△△	0.37±0.03	-	3.52±0.32^△	14.74±2.40
BCG+PD+SP+SB	-	1.17±0.15^△△	0.94±0.08	-	7.60±0.79^△△	22.78±1.76

Bioinformatic analysis on regulatory mechanism of MAPK-Mcl-1 signaling pathway and macrophage polarization during Bacillus Calmette-Guérin infection and its experimental validation

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 23

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Wei ZHOU,Yangyang HE,Youde WANG,Wenzhuo MA,Heng KANG. Effect of histone deacetylase 6 inhibitor ACY-241 on macrophage polarization and biological behaviors of esophageal cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 621-632.
[2]	Xiaohui LIANG,Wenna LIU,Jianbo ZHAO. Bioinformatic analysis on PAQR3 expression in hepatocellular carcinoma and its correlations with T lymphocyte infiltration, immune checkpoint genes, and patient survival [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 781-790.
[3]	Zhipeng PAN,Le WANG,Weiwen HUANG,Zhen YI,Yuxuan GAO. Bioinformatics analysis and experimental validation based on screening and identification of diagnostic candidate genes of bone marrow mononuclear cells of acute myeloid leukemia patients and their impact on prognosis [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 791-805.
[4]	Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409.
[5]	Jingyuan WANG,Fang CHEN,Yancun LIU,Shixin LI,Songtao SHOU. Protective effect of silencing coagulation factor V gene on septic rats by inhibiting JNK1/2 and p38 MAPK signaling pathways [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 418-428.
[6]	Jingyuan WANG,Fang CHEN,Yancun LIU,Shixin LI,Songtao SHOU. Effect of USF2 knockdown on coagulation dysfunction in septic rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 171-181.
[7]	Xiao LIN,Meng ZHOU,Fan LIN,Xiujuan YAO. Bioinformatics analysis and experimental validation of fatty acid metabolism-related genes in idiopathic pulmonary fibrosis tissue [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 93-104.
[8]	Yu LIANG,Jinyu YU,Zhonggao XU,Wanning WANG. Expression characteristics of FOSB in kidney tissue from IgA nephropathy and other common kidney diseases [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1281-1292.
[9]	Weigao SHEN,Yuqi LIU,Jun ZHANG,Jiayu LIN,Hang CUI,Yanbo LIU. Bioinformatics analysis on effect of interleukin-33 on occurrence and development of malignant brain glioma and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1318-1332.
[10]	Linrui XU,Yiyu ZHANG,Jiaqi CUI,Xianzhu CONG,Shuang LI,Jiayu GE,Yujia KONG,Suzhen WANG,Fuyan SHI,Jinrong WANG. Construction of diagnostic model for Alzheimer’s disease and immune analysis based on bioinformatics and machine learning [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1039-1051.
[11]	Xianwei JIANG,Minghang WANG,Huiru LI,Xiaosheng DONG,Yuanyuan LIU. Mendelian randomization and GEO database identification analysis based on potential therapeutic targets for chronic obstructive pulmonary disease [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1072-1083.
[12]	Kun YANG,Qianyao FU,Yongqiang SUN,Kun YANG,Jun MENG. Protective effect of dexmedetomidine on intestinal mucosal injury in rats with enterogenous sepsis and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 855-865.
[13]	Changyu SHI,Yong LI,Jing DENG,Chunmei PIAO,Ming JIN. Bioinformatics analysis on adjustment effect of colorectal liver metastases model in mice based on complement alternative pathway and its experimental verification [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 703-715.
[14]	Chongyang ZHANG,Jia LUO,Xue QIN,Panxi SUN,Lili WEI,Xiushi YU. Protective effect of prunetin on cerebral ischemia-reperfusion injury in rats by regulating JNK/p38 pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 296-306.
[15]	Wenchang CAI,Yuqi LIU,Han WANG,Helin WANG,Zhenjiang WANG,Zishen XIAO,Shiyuan MA,Liping AN,Yanbo LIU. Expression of protein kinase D2 in bladder cancer tissue and its effect on tumor immune microenvironment [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 378-391.